CANC
Tema Oncology ETF
Price Chart
Latest Quote
$41.52
+0.48 (+1.18%)
Current Price
| Previous Close | $41.04 |
| Open | $40.75 |
| Day High | $41.73 |
| Day Low | $40.68 |
| Volume | 8,112 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.05% |
| Net Assets | $208.60M |
| Expense Ratio | 0.75% |
| Category | Health |
| Fund Family | Tema ETFs |
| Net Asset Value | $40.97 |
| Premium/Discount | 1.36% |
| Quarterly Dividend Yield | 0.05% |
| P/E Ratio | 26.12 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $40.80 |
| SMA50 | $42.13 |
| SMA200 | $39.18 |
| RSI | 55.51 |
| ATR | 0.9636 |
| Rel Volume | 0.32 |
Performance History
| Week | -0.16% |
| Month | -0.27% |
| Quarter | +2.25% |
| 6 Months | +11.41% |
| YTD | +20.05% |
| Year | +38.30% |
| 3 Years | +93.67% |
| 10 Years | +1080.08% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $41.53 | 8,112 |
| 2026-10-26 | $40.99 | 13,600 |
| 2026-10-23 | $41.29 | 12,600 |
| 2026-10-22 | $41.49 | 10,300 |
| 2026-10-21 | $41.53 | 16,800 |
| 2026-10-20 | $41.59 | 12,100 |
| 2026-10-19 | $40.01 | 26,000 |
| 2026-10-16 | $39.65 | 7,100 |
| 2026-10-15 | $40.68 | 24,200 |
| 2026-10-14 | $39.73 | 21,800 |
| 2026-10-13 | $39.26 | 14,800 |
| 2026-10-12 | $40.58 | 10,900 |
| 2026-10-09 | $40.78 | 13,000 |
| 2026-10-08 | $40.13 | 21,100 |
| 2026-10-07 | $40.62 | 24,600 |
| 2026-10-06 | $40.46 | 24,900 |
| 2026-10-05 | $41.35 | 77,300 |
| 2026-10-02 | $40.99 | 44,900 |
| 2026-10-01 | $41.31 | 69,200 |
| 2026-09-30 | $42.01 | 46,800 |
| 2026-09-29 | $42.01 | 11,700 |
| 2026-09-28 | $41.64 | 18,900 |
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on CANC.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.